Created in 2024 through the merger of Mipharm, Doppel, and Alfa Omega and headquartered in Milan, DMX operates as a contract developer and finished dosage form (FDF) manufacturer for generic pharmaceutical products, while food supplements account for a small share of its business (~5% of 2024 revenues). DMX produces 190+ products in solid, semi-solid, and liquid dosage forms. The company operates three plants in Northern Italy with 33 manufacturing lines and 41 packaging lines, plus a small facility in Ferrara dedicated to nutraceuticals and homeopathic products. DMX Pharma boasts a portfolio of 100+ clients, including both pharma companies (e.g., Novartis, Adare, GSK, Bayer) and global generic players (e.g., EG, DOC, Cipla, Sandoz).